Drug trial may replace chemotherapy for some cancer patients

A new drug trial shows promising results, potentially replacing chemotherapy and surgery with immunotherapy for certain cancer patients. The drug, dostarlimab, has shown complete remission in some patients. The Memorial Sloan Kettering Cancer Center trial involved 103 patients with specific genetic mutations. Patients with mismatch repair deficiency saw their tumors disappear entirely after receiving dostarlimab, an immunotherapy drug. The trial's success could revolutionize cancer treatment, particularly for those with rectal cancer. The study highlights the potential of immunotherapy to reduce the need for invasive procedures and harsh treatments.